Specialty code 1835P2201X · Oakland, CA
NPI
1699446252
Since 2021
Specialty
Specialty code 1835P2201X
Code 1835P2201X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
3772 Howe St., Ground Floor G30
Oakland, CA, 94611
Phone (510) 752-6684
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$111K
749 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug William T DO prescribed most often to Medicare patients was Insulin Glargine-Yfgn, with 197 prescriptions and refills. In total William T DO wrote 749 Medicare prescriptions that cost $111K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-09-23.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Insulin Glargine-Yfgn Generic | 197 | 563 | 69 | $20K |
| Humalog Kwikpen U-100 Insulin Lispro | 102 | 228 | 35 | $32K |
| Humalog Insulin Lispro | 102 | 308 | 35 | $22K |
| Atorvastatin Calcium Generic | 58 | 185 | 23 | $732 |
| Lisinopril Generic | 42 | 116 | 13 | $448 |
| Losartan Potassium Generic | 26 | 87 | 11 | $357 |
| Humalog Junior Kwikpen Insulin Lispro | 16 | 35 | Under 11 | $3,670 |
| Ultra-Fine Mini Pen Needle Pen Needle, Diabetic | 16 | 51 | Under 11 | $681 |
| Ultra-Fine Nano Pen Needle Pen Needle, Diabetic | 16 | 32 | Under 11 | $576 |
| Baqsimi Glucagon | 15 | 15 | 14 | $9,150 |
| Amlodipine Besylate Generic | 15 | 48 | Under 11 | $174 |
| Lisinopril-Hydrochlorothiazide Lisinopril/Hydrochlorothiazide | 11 | 28 | Under 11 | $148 |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 11 | 36 | Under 11 | $332 |
Brand drugs: 464 claims; generic drugs: 211 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to William T DO were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.